[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Dahse R, Kosmehl H: Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer; 2008 Jul 8;99(1):90-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
  • By screening salivary gland carcinoma, two drug-sensitizing EGFR exon 19 delE746-A750 mutations were identified in an adenocystic and in a mucoepidermoid carcinoma of the parotid gland.
  • [MeSH-major] Drug Resistance / genetics. Parotid Neoplasms / drug therapy. Parotid Neoplasms / genetics. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Aged. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / genetics. DNA, Neoplasm / genetics. Erlotinib Hydrochloride. Exons. Female. Humans. Male. Middle Aged. Mutation. Quinazolines / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] Pathol Int. 2007 May;57(5):233-44 [17493170.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • (PMID = 18542074.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC2453031
  •  go-up   go-down


2. Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, Madami L: Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):182-90
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major salivary gland diseases. Multicentre study.
  • This multicentre study involved 28 Italian ORL Centres responding to a questionnaire sent by us which allowed recruitment of a high large number of cases of parotid neoplasms observed over a 10-year period.
  • Malignant tumours instead were fewer in number compared to the literature (14% vs 25-30%); the most frequent being mucoepidermoid carcinoma (18.2%) of which 44% G1, 33% G2 and 23% G3.
  • Adenoid-cystic carcinoma was observed in 15.3% and < or = 10% for all the other most frequent histological malignant neoplasms.
  • Diagnostic work-up included echotomography and fine-needle aspiration biopsy, less used imaging techniques were computed tomography, magnetic resonance imaging, Sialo-computed tomography.
  • Surgical treatment of benign tumours consisted, in 50% of cases, in superficial paroditectomy and in approximately 30% of total paroditectomy.
  • The lateral neck dissection most frequently carried out was of functional type in 54% and selective type in 46% with removal of levels I-III and II-IV in approximately 60% of cases.
  • Post-operative-complementary radiotherapy was very frequently performed instead of chemotherapy.
  • Oncological results obtained were compared with those reported in the literature: in fact for all benign neoplasms relapse ratings are about 5%, while for malignant tumours the worst prognosis was in squamous cell carcinoma with median of 37.7 on survival and metastasis rate of 16.5%.
  • Finally, mucoepidermoid carcinoma tumours showed best survival, followed by adenoid-cystic carcinoma with ranges, respectively, 83 and 81.
  • [MeSH-major] Salivary Gland Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1984-8 [11801983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):729-38 [11849796.001]
  • [Cites] Atlas Oral Maxillofac Surg Clin North Am. 1998 Mar;6(1):1-28 [11905347.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):285-7 [11945190.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Apr;22(2):80-5 [12068476.001]
  • [Cites] J Laryngol Otol. 2002 May;116(5):359-62 [12080993.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Mund Kiefer Gesichtschir. 2003 Mar;7(2):94-101 [12664254.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):257-9 [12903612.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):624-9 [12956917.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):929-33 [12975263.001]
  • [Cites] World J Surg. 2003 Jul;27(7):863-7 [14509520.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Chir Ital. 2003 Nov-Dec;55(6):857-64 [14725226.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Otolaryngol Pol. 2004;58(1):109-14 [15101269.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):113-27 [15062365.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Feb;23(1):53-6 [15804023.001]
  • [ErratumIn] Acta Otorhinolaryngol Ital. 2005 Oct;25(5):following 337
  • (PMID = 16450775.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639866
  •  go-up   go-down


3. Miyatima Y, Ogawa A, Kuno K, Toda K, Suzuki K, Mituya A: [Mucoepidermoid carcinoma of the parotid gland as a secondary malignancy developed ten years after chemotherapy for childhood acute lymphoblastic leukemia]. Rinsho Ketsueki; 2007 Jun;48(6):491-4
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucoepidermoid carcinoma of the parotid gland as a secondary malignancy developed ten years after chemotherapy for childhood acute lymphoblastic leukemia].
  • We report on a case of mucoepidermoid carcinoma of the parotid gland following treatment of acute lymphoblastic leukemia (ALL) in childhood.
  • Treatment included multidrug chemotherapy and prophylactic 18 Gy cranial irradiation.
  • She developed low-grade mucoepidermoid carcinoma of the right parotid gland at the age of 24 years, the most probable cause of the secondary malignancy being radiation.
  • In a literature review of mucoepidermoid carcinoma following ALL, 11 out of 14 cases received radiation therapy for the initial treatment of ALL, but 3 cases had no radiation therapy.
  • The parotid gland carcinoma as a secondary malignancy following ALL in childhood is rare, but it highlights the need for concern about the secondary malignancy in patients with painless parotid swelling after chemoradiotherapy.
  • [MeSH-major] Carcinoma, Mucoepidermoid / etiology. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Female. Humans. Radiotherapy / adverse effects. T-Lymphocytes. Time Factors. Treatment Outcome


Advertisement
4. Savelli SL, Klopfenstein KJ, Termuhlen AM: Mucoepidermoid carcinoma of the parotid gland as a second malignant neoplasm. Pediatr Blood Cancer; 2005 Dec;45(7):997-1000
Genetic Alliance. consumer health - Mucoepidermoid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the parotid gland as a second malignant neoplasm.
  • We report two second malignant neoplasms (SMNs) of the parotid gland.
  • Eight years after her initial diagnosis she presented with a small, painless mass in the region of her parotid gland.
  • Thirteen years after her initial diagnosis she presented with a painless mass in her right cheek.
  • Pathology revealed low-grade mucoepidermoid carcinoma (MEC) in both cases.
  • [MeSH-major] Carcinoma, Mucoepidermoid / surgery. Leukemia, B-Cell / drug therapy. Neoplasms, Second Primary / surgery. Parotid Neoplasms / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley-Liss, Inc.
  • (PMID = 15602710.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Selesnick SH, Burt BM: Regional spread of nonneurogenic tumors to the skull base via the facial nerve. Otol Neurotol; 2003 Mar;24(2):326-33
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five patients received adjuvant radiation, and two received adjuvant radiation and chemotherapy.
  • RESULTS: Five cases of malignancy were reported: one case of parotid adenoid cystic carcinoma, one case of parotid mucoepidermoid carcinoma, two cases of squamous cell carcinoma of the skin, and one case of an unidentified carcinoma.
  • In addition, one case of benign pleomorphic adenoma of the parotid gland that circumferentially involved an intratemporal segment of the facial nerve was reported.
  • Four patients had unresectable malignant disease, and two died despite multimodality therapy.
  • [MeSH-major] Carcinoma / pathology. Cranial Nerve Neoplasms / pathology. Facial Nerve / pathology. Parotid Neoplasms / pathology. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621352.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


6. Rutigliano DN, Meyers P, Ghossein RA, Carlson DL, Kayton ML, Kraus D, La Quaglia MP: Mucoepidermoid carcinoma as a secondary malignancy in pediatric sarcoma. J Pediatr Surg; 2007 Jul;42(7):E9-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma as a secondary malignancy in pediatric sarcoma.
  • PURPOSE: Children diagnosed with osteosarcoma (OS) and Ewing sarcoma (ES) have greatly benefited from the addition of alkylator therapy.
  • Herein we report on 2 patients with sarcoma who developed a case of secondary mucoepidermoid carcinoma after chemotherapy treatment without associated radiation therapy.
  • To our knowledge, this is the first series of mucoepidermoid carcinomas arising in pediatric patients treated for sarcoma without radiotherapy.
  • Details of their initial evaluation, previous therapies, resection techniques, pathologic findings, and follow-up compose this report.
  • RESULTS: Two patients, a 17-year-old adolescent boy with OS and 16-year-old adolescent girl with ES, with secondary mucoepidermoid carcinoma of the parotid gland were identified.
  • Both patients underwent primary resection and chemotherapy including alkylating agents, but neither received radiation.
  • The mucoepidermoid carcinomas developed 27 months and 132 months after completion of therapy, respectively, and were noted on routine yearly follow-up.
  • Pathology revealed low-grade mucoepidermoid carcinoma with tumor extending to the deep margins for both lesions, and radiotherapy to the parotid bed was administered.
  • One patient is alive, without evidence of recurrent mucoepidermoid carcinoma after 4 years; the other recently completed radiotherapy and is disease-free after 12 months.
  • CONCLUSION: Primary mucoepidermoid carcinoma of the parotid gland accounts for less than 10% of all head and neck tumors in childhood.
  • Previous series of secondary mucoepidermoid carcinoma have demonstrated an increased risk in patients with leukemia/lymphoma.
  • This is the first reported series of parotid mucoepidermoid carcinomas occurring after sarcoma treatment without radiotherapy.
  • A common link between the 2 patients may be the use of alkylating therapy.
  • [MeSH-major] Bone Neoplasms / pathology. Carcinoma, Mucoepidermoid / pathology. Neoplasms, Second Primary / pathology. Osteosarcoma / pathology. Parotid Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Female. Humans. Male

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618873.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Sandoval C, Jayabose S: Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2001 Apr-May;18(3):217-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia.
  • Primary parotid gland tumors are rare during childhood; however, these tumors are more common as second malignant neoplasms following radiation therapy.
  • The authors report a case of secondary parotid mucoepidermoid carcinoma after chemotherapy for childhood acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Mucoepidermoid / chemically induced. Neoplasms, Second Primary / chemically induced. Parotid Neoplasms / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


8. Boccon-Gibod L, Boman F, Josset P, Landman-Parker J: Mucoepidermoid carcinoma of the parotid gland in a child previously treated for acute lymphoblastic leukemia. Pediatr Blood Cancer; 2005 Jun 15;44(7):673-5
Genetic Alliance. consumer health - Mucoepidermoid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the parotid gland in a child previously treated for acute lymphoblastic leukemia.
  • Occurrence of second cancers is a major concern for the care of children cured of cancer.
  • Children treated for acute lymphoblastic leukemia (ALL) have an increased risk for developing mucoepidermoid carcinomas (MEC) of the parotid gland.
  • Treatment included multidrug chemotherapy and prophylactic intrathecal injections of methotrexate and prednisolone.
  • Low-grade MEC of the left parotid gland was diagnosed at the age of 7 years, only 1 year after completing treatment.
  • This case report is remarkable for the early diagnosis of second cancer, only 4 years after diagnosis of ALL, and its occurrence in parotid gland without previous head and neck irradiation.
  • It highlights the need for concern about second cancers of the parotid gland in children treated for ALL.
  • [MeSH-major] Carcinoma, Mucoepidermoid / etiology. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15515042.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


9. Manzitti C, Mereu P, Haupt R, Di Blasi A, Bellani FF, Dallorso S: Parotid carcinoma after autologous bone marrow transplantation for relapsed nephroblastoma. J Pediatr Hematol Oncol; 2003 Aug;25(8):672-3
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid carcinoma after autologous bone marrow transplantation for relapsed nephroblastoma.
  • Abdominal irradiation, especially if associated with doxorubicin administration, increases the risk of a secondary malignant neoplasm (SMN) after treatment of nephroblastoma.
  • The authors describe the case of a parotid mucoepidermoid carcinoma arising 13 years after diagnosis of nephroblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / etiology. Carcinoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Parotid Neoplasms / pathology. Wilms Tumor / drug therapy. Wilms Tumor / radiotherapy
  • [MeSH-minor] Adult. Doxorubicin / administration & dosage. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12902928.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


10. Hatta C, Terada T, Okita J, Kakibuchi M, Kubota A, Sakagami M: Clinicopathological study of undifferentiated carcinoma of the parotid gland. Auris Nasus Larynx; 2003 Aug;30(3):273-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of undifferentiated carcinoma of the parotid gland.
  • OBJECTIVE: Undifferentiated carcinoma of the salivary gland is a rare malignant tumor, and is difficult to distinguish from other poorly differentiated types of carcinoma or sarcoma.
  • The present study investigated clinical and pathological characteristics for undifferentiated carcinoma of the parotid gland.
  • PATIENTS AND METHODS: Forty-four patients with previously untreated carcinoma of the major salivary glands were treated at our institution between 1986 and 1999.
  • Of these, five patients (two males, three females) were diagnosed with undifferentiated carcinoma of the parotid gland and treated.
  • Tumors in these two patients included a small portion of poorly differentiated epidermoid or mucoepidermoid carcinoma.
  • The remaining three patients did not show any differentiated portions, and histological findings demonstrated heterogeneous patterns of lymphoepithelial carcinoma, small cell carcinoma and unclassified (a pattern of malignant hemangiopericytoma), respectively.
  • CONCLUSIONS: Investigation using multislice sections is needed to diagnose undifferentiated carcinoma of the salivary glands.
  • Regarding prognosis, carcinoma that is too poorly differentiated but including slightly-differentiated portions should be considered undifferentiated carcinoma.
  • All patients died of distant metastasis despite radical surgery, suggesting that chemotherapy is needed to improve patient outcomes.
  • [MeSH-major] Carcinoma / pathology. Parotid Gland / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12927291.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Hicks J, Flaitz C: Mucoepidermoid carcinoma of salivary glands in children and adolescents: assessment of proliferation markers. Oral Oncol; 2000 Sep;36(5):454-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of salivary glands in children and adolescents: assessment of proliferation markers.
  • Malignant neoplasms represent one-third of all pediatric salivary gland tumors.
  • Mucoepidermoid carcinoma (MEC) composes 51% of malignant tumors and 16% of all salivary gland neoplasms in pediatrics.
  • Histopathologic features, clinical outcomes and proliferation markers in 26 pediatric patients (median age 11 years; 19F:7M) with salivary gland MECs were evaluated retrospectively.
  • Tumor site was 16 parotid, eight submandibular, one base of tongue and one maxillary lip.
  • Treatment was surgical in 21 cases, and surgery with chemotherapy and radiotherapy in five cases.
  • MECs were second malignancies in two children with prior radiotherapy and chemotherapy for leukemia and histiocytosis.
  • Low and intermediate grade salivary gland MECS in a pediatric population may have a favorable outcome when compared with high grade MECs.
  • Proliferation markers appear to be linked to histocytologic MEC grade and may provide information regarding biologic behavior of salivary gland MECs in children and adolescents.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Mucoepidermoid / chemistry. Salivary Gland Neoplasms / chemistry

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10964053.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


12. Charabi S, Balle V, Charabi B, Nielsen P, Thomsen J: Surgical outcome in malignant parotid tumours. Acta Otolaryngol Suppl; 2000;543:251-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome in malignant parotid tumours.
  • Of 494 parotid gland tumours treated in Copenhagen county (population 600,000 inhabitants) in the period 1986-95, 50 patients (34 males, 16 females) had tumours that were proven to be malignant, making an incidence of 0.62/100,000/year.
  • The material included 41 primary parotid gland tumours, histologically the tumours were verified as mucoepidermoid carcinoma (n = 13), adenocarcinoma (n = 9), squamous cell carcinoma (n = 6), carcinoma ex pleomorph adenoma (n = 3), acinic cell carcinoma (n = 3), adenoid cystic carcinoma (n = 3) and other histological diagnoses (n = 4).
  • Primary malignant lymphoma of the parotid gland was diagnosed in six tumours and the last three tumours were metastatic carcinoma.
  • Four therapeutic modalities were applied: surgery only, surgery + radiation, surgery + chemotherapy, and surgery + chemotherapy + radiation.
  • [MeSH-major] Parotid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Catchment Area (Health). Combined Modality Therapy. Denmark / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10909035.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NORWAY
  •  go-up   go-down


13. Obaid MA, Yusuf A: Surgical management of epithelial parotid tumours. J Coll Physicians Surg Pak; 2004 Jul;14(7):394-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of epithelial parotid tumours.
  • OBJECTIVE: To describe the clinicopathological presentation and treatment options in epithelial parotid tumours with emphasis on surgery.
  • SUBJECTS AND METHODS: Epithelial parotid tumours diagnosed and operated by an ENT surgeon and a general surgeon in 10 years during their posting in different teaching hospitals were included in the study.
  • Clinical presentation, preoperative investigations, operative procedure, histopathology report, postoperative complications and further management were recorded.
  • RESULTS: Fifty-two patients presented with parotid tumour.
  • Commonest presentation was a painless lump over the parotid region (85%), pain (15%), facial palsy, and enlarged neck nodes.
  • Parotid pleomorphic Adenoma (PPA) was the commonest benign tumour, others being Warthin's tumour and monomorphic adenoma.
  • Adenoid cystic carcinoma was the commonest malignant tumour 29% followed by mucoepidermoid carcinoma.
  • Others were carcinoma in PPA, squamous cell carcinoma, malignant mixed tumour, malignant lymphoepithelioma and undifferentiated carcinoma.
  • Except for one child, rest of the 13 patients received postoperative radiotherapy and one patient of lymphoepithelioma received chemotherapy in addition.
  • CONCLUSION: Benign and malignant epithelial parotid tumours can be diagnosed by their clinical presentation supplemented with FNAC.
  • Radical parotidectomy followed by radiotherapy and in selected cases neck node dissection are the recommended procedures for advanced malignant parotid tumours.
  • [MeSH-major] Adenoma, Pleomorphic / surgery. Parotid Gland / surgery. Parotid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Glandular and Epithelial / mortality. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / surgery. Postoperative Complications. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15279739.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


14. Cheuk DK, Shek TW, Chan GC, Lau YL, Ha SY, Chiang AK: Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Mar;50(3):636-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
  • Secondary malignancies are an important cause of morbidity and mortality in childhood cancer survivors.
  • Salivary gland tumors account for about 6% of the second cancers.
  • The majority of these are mucoepidermoid carcinomas (MEC) of the parotid gland.
  • We report the clinical and pathological features of a rarer histological type, acinic cell carcinoma (ACC), in a childhood acute lymphoblastic leukemia (ALL) survivor.
  • The behavior of secondary ACC appears similar to primary tumor and similar treatment may be adopted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Acinar Cell / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Whole-Body Irradiation / adverse effects
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. 6-Mercaptopurine / adverse effects. Adenoma, Sweat Gland / etiology. Adenoma, Sweat Gland / surgery. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child, Preschool. Combined Modality Therapy / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Prednisolone / administration & dosage. Prednisolone / adverse effects. Recurrence. Remission Induction. Survivors. Sweat Gland Neoplasms / etiology. Sweat Gland Neoplasms / surgery. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16865683.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; UKALL X protocol
  • [Number-of-references] 17
  •  go-up   go-down


15. Taxy JB: Squamous carcinoma in a major salivary gland: a review of the diagnostic considerations. Arch Pathol Lab Med; 2001 Jun;125(6):740-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous carcinoma in a major salivary gland: a review of the diagnostic considerations.
  • CONTEXT: Squamous carcinoma in a major salivary gland has several possible sources:.
  • (1) high-grade mucoepidermoid carcinoma, (2) metastasis or direct invasion from a primary skin carcinoma, (3) metastasis from a distant primary carcinoma, or (4) a primary malignant neoplasm.
  • The latter is conventionally regarded as a diagnosis of exclusion after a history of squamous carcinoma elsewhere has been obtained or there is a positive mucin stain.
  • DESIGN: Eleven cases of squamous carcinoma in a major salivary gland are presented and the literature reviewed.
  • RESULTS: Two cases, 1 metastatic from a histologically identical squamous carcinoma from the ipsilateral tonsil and 1 with in situ squamous carcinoma in a duct, demonstrated positive mucicarmine stains.
  • Two cases were high-grade mucoepidermoid carcinomas, also with positive mucin stains.
  • CONCLUSION: The occurrence of squamous carcinoma in a major salivary gland exhibits a histologic sameness that precludes accurate subclassification and assignation of origin.
  • Also irrespective of tumor origin, the clinical approach to diagnosis and treatment is similar.
  • Adjuvant therapy (eg, radical neck dissection, radiation, chemotherapy) is not uniformly applied.
  • The traditional subclassification of squamous carcinoma in a major salivary gland may not be clinically relevant.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Mucins / metabolism. Parotid Neoplasms / metabolism. Parotid Neoplasms / pathology. Parotid Neoplasms / secondary. Submandibular Gland Neoplasms / metabolism. Submandibular Gland Neoplasms / pathology. Submandibular Gland Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371224.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 18
  •  go-up   go-down


16. Pacheco-Ojeda L, Domeisen H, Narvaez M, Tixi R, Vivar N: Malignant salivary gland tumors in Quito, Ecuador. ORL J Otorhinolaryngol Relat Spec; 2000 Nov-Dec;62(6):296-302
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant salivary gland tumors in Quito, Ecuador.
  • OBJECTIVES: Malignant salivary gland tumors (MSGT) are uncommon.
  • The goal of this study was to review a 16-year experience of a major general hospital in the treatment of these lesions.
  • PATIENTS AND METHODS: From 1982 to 1998, 308 salivary gland tumors were surgically treated at the Hospital 'Carlos Andrade Marin' of the Ecuadorian Institute of Social Security in Quito, Ecuador, an Andean city of approximately 2 million inhabitants.
  • Malignant lesions were found in 58 cases (19%): 37 out of 194 parotid gland tumors (19%), 7 out of 86 submandibular tumors (8%) and 14 out of 28 minor salivary gland tumors (50%).
  • Adenoid cystic carcinoma and mucoepidermoid carcinoma were the most common histologic types.
  • Thirty-one (53%) patients were treated by surgery alone; postoperative radiation therapy was additionally given to 22 (38%), and surgery, radiotherapy and chemotherapy were applied in 5 cases (9%).
  • Twelve patients (21%) developed distant metastasis (DM; 2 in more than one site): 7 in the lungs, 2 in the brain, 2 in the bone and 1 each in the liver, subcutaneous tissue and pleura.
  • There were no significant differences in mortality according to the site of the primary tumor or histologic type, but stage and involved surgical margins were important prognostic factors (p = 0.006 and 0.003).
  • CONCLUSIONS: The surgical or multimodality treatment of MSGT has provided a good locoregional control (78%) and 68% 10-year survival in a series of patients treated at the oncology department of a general hospital in Quito, Ecuador.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Carcinoma, Mucoepidermoid / therapy. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Ecuador / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Salivary Glands / pathology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 11054011.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 31
  •  go-up   go-down


17. Bradley P, McClelland L, Mehta D: Paediatric salivary gland epithelial neoplasms. ORL J Otorhinolaryngol Relat Spec; 2007;69(3):137-45
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric salivary gland epithelial neoplasms.
  • Salivary gland epithelial neoplasms in children are rare.
  • Clinicians of all disciplines need to have a high level of suspicion when a non-inflammatory single mass lesion presents in the parotid or submandibular glands.
  • Surgery is the primary treatment of choice in the majority of cases, with the addition of adjuvant radiotherapy +/- chemotherapy when the diagnosis is a high-grade tumour and/or when the malignancy presents as a large mass or is associated with local tissue invasion.
  • Minor salivary gland neoplasms also present, the oral cavity is most frequent, with pleomorphic adenoma and mucoepidermoid carcinoma being most common, other malignant neoplasms have been reported in other sites.
  • [MeSH-major] Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Carcinoma / classification. Carcinoma / pathology. Carcinoma / surgery. Child. Child, Preschool. Epithelium / pathology. Humans. Infant. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17264529.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 46
  •  go-up   go-down


18. Bell RB, Dierks EJ, Homer L, Potter BE: Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg; 2005 Jul;63(7):917-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and outcome of patients with malignant salivary gland tumors.
  • PURPOSE: Refined imaging technology, the use of external beam radiation, neutron beam therapy, and chemotherapy, has altered management strategies for patients with salivary gland malignancies during the past 2 decades.
  • Although treatment remains primarily surgical, optimal therapeutic regimens have yet to be fully realized.
  • The purpose of this investigation is to report our experience with the management of patients with a variety of malignant salivary gland neoplasms that were treated with various combinations of surgery, radiation, and chemotherapy and to review treatment outcome in an effort to identify predictors of survival and locoregional control.
  • MATERIALS AND METHODS: The records of all patients with malignant salivary gland tumors presenting for treatment at our institution between 1992 and 2002 were retrospectively reviewed.
  • The majority of tumors were located in the parotid gland (n = 42), with a significant minority located in the minor salivary glands (n = 29), followed by the submandibular gland (n = 8) and the sublingual gland (n = 6).
  • Mucoepidermoid carcinoma was the most common neoplasm (n = 40).
  • Neck dissection was performed in 29% of patients, and more than half (56%) were treated with adjuvant external beam radiation therapy to a dose of 50 to 70 Gy.
  • Patients were, in general, immediately reconstructed at the time of ablation using composite free tissue transfer when appropriate, local/regional rotational flaps, or maxillary obturators.
  • CONCLUSIONS: The treatment of salivary gland malignancies remains primarily surgical, although adjunctive radiotherapy may play an important role in those patients with advanced-stage disease.
  • The benefits of combined modality therapy awaits prospective clinical trials.
  • [MeSH-major] Carcinoma / therapy. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Invasiveness / prevention & control. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16003616.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Oudidi A, El-Alami MN, Boulaich M, Jazouli N, Kzadri M: [Primary sub-mandibular gland tumours: experience based on 68 cases]. Rev Laryngol Otol Rhinol (Bord); 2006;127(3):187-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary sub-mandibular gland tumours: experience based on 68 cases].
  • [Transliterated title] Les tumeurs primitives de la glande sous-maxillaire: à propos de 68 cas.
  • Sub-mandibulary gland tumours are less common than tumours of the parotid and pose many clinical and therapeutic challengers.
  • PATIENTS AND METHODS: Retrospective studies of sub-mandibular gland tumours presenting to our department between 1986 and 2000.
  • Definitive diagnosis was by complete excision and pathological examination.
  • For malignant lesions (n= 31) the most frequent were: Adenoid cystic carcinoma (n= 10), epidermoid carcinoma (n= 5), adenocarcinoma (n= 5), mucoepidermoid carcinoma (n= 3), malignant non Hodgkinien lymphoma (n= 5).
  • Treatment was by total surgical excision of the submandibular gland for the begnin tumours.
  • Radiotherapy was performed in 24 cases and chemotherapy in 10 cases.
  • CONCLUSION: Malignity in sub-mandibular gland tumours is more frequent than in the parotid gland.
  • Any delay in diagnosis or inappropriate management may result in a poor prognosis for the patient.
  • [MeSH-major] Submandibular Gland Neoplasms / classification. Submandibular Gland Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Early Diagnosis. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007195.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Piccinelli KJ, Taj M, Lucraft HH, Skinner R: Secondary parotid mucoepidermoid carcinoma after TBI and chemotherapy in childhood AML. Pediatr Blood Cancer; 2006 Sep;47(3):345-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary parotid mucoepidermoid carcinoma after TBI and chemotherapy in childhood AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Mucoepidermoid / diagnosis. Leukemia, Myeloid, Acute / therapy. Neoplasms, Second Primary / diagnosis. Parotid Neoplasms / diagnosis. Whole-Body Irradiation / adverse effects
  • [MeSH-minor] Adult. Follow-Up Studies. Humans. Male. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16572403.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement